Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 10/20 | 0.57 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | LCAT | P04180 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787776 | 0.80 | GPR119 (0.57) | PANK3GPR119CKS1BSKP1SKP2 | |
| SCHEMBL29631957 | 0.80 | PANK3 (0.55) | PANK3CKS1BSKP1SKP2 | |
| SCHEMBL18855709 | 0.79 | AR (0.46) | PANK3PARP1PARP2RIPK1JAK2 | |
| SCHEMBL26127143 | 0.78 | CTSS (0.46) | PANK3PARP1PARP2CKS1BSKP1 | |
| SCHEMBL27226900 | 0.78 | GPR119 (0.54) | PANK3RIPK1GPR119 | |
| SCHEMBL19748850 | 0.78 | PANK3 (0.61) | PANK3PARP1PARP2CHRM4 | |
| SCHEMBL2894290 | 0.78 | AOC3 (0.45) | PANK3PARP1LCAT | |
| SCHEMBL24242896 | 0.77 | AR (0.49) | PANK3PARP1PARP2RIPK1JAK2 | |
| SCHEMBL3787774 | 0.77 | CHRM4 (0.49) | PANK3PARP1PARP2RIPK1JAK2 | |
| SCHEMBL20355456 | 0.77 | PANK3 (0.46) | PANK3PARP1PARP2RIPK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-08-12 | — | — | US | disclosed |
| EP-3562822-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Mitobridge, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2019-10-03 | — | — | US | disclosed |
| EP-3474667-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | St. Jude Children's Research Hospital, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2018125961-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| WO-2017223474-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-12-28 | — | — | WO | disclosed |
| CN-101287722-A | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | PANK3 3/4885PARP1 500/4885PARP2 421/4885 |
| US-20190300499-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | PANK3 3/4885PARP1 500/4885PARP2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.